Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Abdenour Nabid
With
AstraZeneca
Age
18–80
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Patients with stage T1 or T2 untreated adenocarcinoma of the prostate, with a Gleason score that is less than or equal to 6, as well as a prostate-specific antigen (PSA) between 10-20 (intermediate risk) or patients with stage T1 or T2 untreated adenocarcinoma of the prostate, with a Gleason score that is equal to 7, as well as a PSA equal to or less than 20 (intermediate risk).
Performance status score of 0-1
Patients must sign a consent form before starting the study.
No evidence of regional disease
Patients with a previous history of cancer are eligible on the condition that they have been disease-free for more than five years.
Non-invasive epidermoid cancers of the skin are eligible.
The patient must be available for treatments and follow-up visits.
No evidence of metastatic disease, confirmed by a negative bone scan.
You may not be if
Severe medical or psychiatric problems that may compromise study compliance
Chronic hepatic disease; abnormal hepatic function, i.e. aspartate aminotransferase and alanine aminotransferase \> 1.5 times the upper normal limit.
